Revagenix
2 known investors
Find your way into Revagenix
258 people in our graph share verified history with the Revagenix team — schools, employers, funds. One of them is your warm intro.
Mariano Rodríguez Monterdeunlockedknows Andrew McCandlish · together at Princeton University (overlapped)
×11knows the team · via Princeton University
Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).
Founders & leadership
RC
Ryan CirzinCo-founder & CEO
AM
Andrew McCandlishinCo-founder & COOAndrew McCandlish is co-founder and COO of Revagenix, a precision-therapeutics company developing drugs for serious chronic diseases. He has prior experience in corporate development, R&D strategy, and program leadership across biotechnology, pharmaceuticals, and medical devices, and has published scientific work.
PS
Peter SmithinChief Scientific Officer
DC
Daniel CloutierinVP, Development
Investors · 2
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BJan 2024 · 2 sources
Tenmile (lead), Novo Holdings
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Revagenix do?
- Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).
- Who founded Revagenix?
- Revagenix was founded by Ryan Cirz, Andrew McCandlish.
- Who are Revagenix's investors?
- Revagenix's investors include Tenmile, Novo Holdings.